Skip to main content

Table 1 CMTC and clinicopathological variables in the internal and external validation cohorts

From: Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations

Variables Internal validation cohort (n = 284) External validation cohort (n = 2,181)
  CMTC-1 number (%) CMTC-2 number (%) CMTC-3 number (%) Pvalue CMTC-1 number (%) CMTC-2 number (%) CMTC-3 number (%) P value
Total 92(32.4) 106(37.3) 86(30.3)   805(36.9) 603(27.6) 773(35.4)  
Age         
 <50 24(26.1) 34(32.1) 21(24.4) 4.52E-01 156(19.4) 92(15.3) 242(31.3) 4.03E-13
 > = 50 68(73.9) 72(67.9) 65(75.6)   649(80.6) 511(84.7) 531(68.7)  
Size         
 <=2 cm 56(60.9) 47(44.3) 40(46.5) 4.71E-02 412(51.6) 221(37.1) 294(38.7) 6.01E-09
 >2 cm 36(39.1) 59(55.7) 46(53.5)   387(48.4) 374(62.9) 465(61.3)  
LN         
 (-) 59(64.1) 68(64.2) 56(65.1) 9.88E-01 499(62.1) 298(49.5) 358(46.6) 6.49E-10
 (+) 33(35.9) 38(35.8) 30(34.9)   305(37.9) 304(50.5) 411(53.4)  
Grade         
 1 20(21.7) 5(4.7) 2(2.3) 8.34E-17 161(21.4) 30(5.2) 16(2.2) 1.36E-125
 2 59(64.1) 37(34.9) 18(20.9)   454(60.3) 253(43.8) 143(19.4)  
 3 13(14.1) 64(60.4) 66(76.7)   138(18.3) 294(51.0) 580(78.5)  
ER         
 (-) 1(1.1) 0(0.0) 57(66.3) 2.20E-35 34(4.2) 17(2.8) 554(71.7) 4.26E-251
 (+) 91(98.9) 106(100.0) 29(33.7)   771(95.8) 586(97.2) 219(28.3)  
HER2+/TN         
 No 90(97.8) 89(84.0) 17(19.8) 4.63E-32 776(96.4) 542(89.9) 180(23.3) 2.58E-251
 Yes 2(2.2) 17(16.0) 69(80.2)   29(3.6) 61(10.1) 593(76.7)  
Eventa         
 No 91(98.9) 100(94.3) 75(87.2) 5.54E-03 686(85.2) 415(68.8) 494(63.9) 3.15E-22
 Yes 1(1.1) 6(5.7) 11(12.8)   119(14.8) 188(31.2) 279(36.1)  
  1. aFollow-up event, recurrence in internal validation cohort, and distant relapse and died from the specific disease in the external validation cohort. CMTC, ClinicoMolecular Triad Classification; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node status; TN, triple-negative.